Drug Approval | March 02, 2022
Amneal enters U.S. biosimilars market with approval of Releukotm
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The new centre will comprise a team of 50 highly experienced specialists
The company has been manufacturing masks since the Covid-19 outbreak in 2020
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Flattish volume growth and subdued new launches were key factors for last month
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The platform’s technology works as a compression algorithm for molecular testing
Subscribe To Our Newsletter & Stay Updated
